Iovance Biotherapeutics
IOVA
IOVA
139 hedge funds and large institutions have $1.05B invested in Iovance Biotherapeutics in 2018 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 67 increasing their positions, 28 reducing their positions, and 25 closing their positions.
Holders
139
Holders Change
+8
Holders Change %
+6.11%
% of All Funds
3.1%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.18%
New
33
Increased
67
Reduced
28
Closed
25
Calls
$1.54M
Puts
$567K
Net Calls
+$968K
Net Calls Change
-$2.56M
Top Buyers
| 1 |
PA
1
Perceptive Advisors
New York
|
$108M |
| 2 |
2
Franklin Resources
San Mateo,
California
|
$73.3M |
| 3 |
3
BlackRock
New York
|
$77.7M |
| 4 |
GPP
4
Great Point Partners
Greenwich,
Connecticut
|
$49.3M |
| 5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$51.1M |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
TI
151
Trexquant Investment
Stamford,
Connecticut
| – | -$278K | -24,732 | Closed |
|
152
D.E. Shaw & Co
New York
| – | -$256K | -22,754 | Closed |
|
|
SAM
153
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$146K | -12,957 | Closed |
|
|
BLA
154
Balter Liquid Alternatives
Boston,
Massachusetts
| – | -$138K | -12,254 | Closed |
|
|
TRCT
155
Tower Research Capital (TRC)
New York
| – | -$99K | -8,842 | Closed |
|
156
Pacer Advisors
Malvern,
Pennsylvania
| – | -$97K | -8,666 | Closed |
|
|
PCM
157
Prelude Capital Management
New York
| – | -$62K | -5,500 | Closed |
|
|
CG
158
Cutler Group
San Francisco,
California
| – | -$56K | -5,000 | Closed |
|
159
BNP Paribas Financial Markets
Paris,
France
| – | -$30.3K | -2,690 | Closed |
|
|
AIM
160
Assured Investment Management
New York
| – | -$8K | -712 | Closed |
|
|
NFG
161
Next Financial Group
Houston,
Texas
| – | -$8K | -700 | Closed |
|